BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 14677267)

  • 1. Is the pharmaceutical market in Bulgaria innovative?
    Stoimenova A; Stankova M; Samev K; Petrova G
    Boll Chim Farm; 2003 Sep; 142(7):260-3. PubMed ID: 14677267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationships between the academic community and the pharmaceutical industry: the legislative background and its effect on spending on medical research and development.
    Matthews JH
    Clin Invest Med; 1996 Dec; 19(6):470-8. PubMed ID: 8959357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategic options for brand-name prescription drugs when patents expire.
    Mehta SC; Mehta SS
    Health Mark Q; 1997; 14(3):107-14. PubMed ID: 10167309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Intellectual property rights and right of access to medicines].
    Velásquez G
    Med Trop (Mars); 2006 Dec; 66(6):526-8. PubMed ID: 17286013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring of national drug policies--regional comparison between Bulgaria, Romania, Macedonia, Bosnia Herzegovina.
    Petrova GI
    Cent Eur J Public Health; 2001 Nov; 9(4):205-13. PubMed ID: 11787250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Early achievements of the Danish pharmaceutical industry-7].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2014; (42):31-62. PubMed ID: 25816561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Packaging of pharmaceuticals: still too many dangers but several encouraging initiatives.
    Prescrire Int; 2007 Jun; 16(89):126-8. PubMed ID: 17585428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. After years of steady growth, winds of restraint blowing on prescription-drug industry.
    Robinson A
    CMAJ; 1995 Jul; 153(1):85-8. PubMed ID: 7796380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry.
    Suh DC; Manning WG; Schondelmeyer S; Hadsall RS
    Health Serv Res; 2000 Jun; 35(2):529-47. PubMed ID: 10857475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brands or generics: the dilemma of pharmaceutical marketing in a developing country.
    Quraeshi ZA; Luqmani M; Malhotra N
    J Health Care Mark; 1983; 3(4):27-37. PubMed ID: 10264767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generics market in Greece: the pharmaceutical industry's beliefs.
    Geitona M; Zavras D; Hatzikou M; Kyriopoulos J
    Health Policy; 2006 Nov; 79(1):35-48. PubMed ID: 16386326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Competition between brand-name and generics--analysis on pricing of brand-name pharmaceutical.
    Kong Y
    Health Econ; 2009 May; 18(5):591-606. PubMed ID: 18816580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Exclusivity of data in drug registration files and Israel's international status with regard to intellectual property rights protection].
    Lipschitz Y; Tamir O; Shemer J
    Harefuah; 2004 Dec; 143(12):845-8, 912. PubMed ID: 15666700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does brand differentiate pharmaceuticals?
    Bednarik J
    Neuro Endocrinol Lett; 2005 Dec; 26(6):635-52. PubMed ID: 16380705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The interaction between intellectual property and drug regulatory systems: global perspectives.
    Madden EA
    IDrugs; 2007 Feb; 10(2):116-20. PubMed ID: 17285464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Strategies for pharmaceutical research and development. II. Generic drugs].
    Kuchar M
    Ceska Slov Farm; 1996 Jul; 45(4):171-6. PubMed ID: 8925240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What's in a name? Generics and the persistence of the pharmaceutical brand in American medicine.
    Greene JA
    J Hist Med Allied Sci; 2011 Oct; 66(4):468-506. PubMed ID: 20858701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.